[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1979

Hypothalamic-Pituitary-Adrenocortical FunctionAssociation With Topical Application of Betamethasone Dipropionate

Author Affiliations

From the Department of Dermatology, Finsen Institute, Copenhagen.

Arch Dermatol. 1979;115(3):362-363. doi:10.1001/archderm.1979.04010030064026
Abstract

Appearance of systemic side effects following topical treatment with corticosteroids is well recognized. Owing to widespread use of corticosteroids for topical application, studies are needed to determine the upper limit of treatment dose by which systemic side effects can be avoided. It has previously been shown that topical treatment with clobetasol propionate (Dermovate [Britain]; no comparable US product) in doses of 18 to 268 g/wk produced abnormal cortisol levels after cosyntropin injection. Although most pronounced at higher doses, adrenal function in some cases also was impaired at doses less than 50 g/wk.1 In this study we assessed hypothalamic-pituitary-adrenocortical (HPA) integrity during a threeweek period of topical treatment with another widely used corticosteroid, betamethasone dipropionate cream. The results showed that treatment with 50 g/wk for three weeks without occlusion did not affect HPA function.

Subjects and Methods  Seventeen patients (eight female, nine male), of whom eight had severe universal psoriasis

First Page Preview View Large
First page PDF preview
First page PDF preview
×